John Bencich - Mar 4, 2024 Form 4 Insider Report for ACHIEVE LIFE SCIENCES, INC. (ACHV)

Role: CEO, Director
Signature: Sandra Thomson as attorney-in-fact for John Bencich
Stock symbol: ACHV
Transactions as of: Mar 4, 2024
Transactions value $: $45,850
Form type: 4
Date filed: 3/6/2024, 04:43 PM
Previous filing: Jan 24, 2024
Next filing: Apr 23, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACHV	Common Stock	Purchase	$45.9K	+10K	+14.99%	$4.59	76.7K	Mar 4, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACHV	Common Stock Warrants (right to buy)	Purchase	$0	+10K		$0.00	10K	Mar 4, 2024	Common Stock	10K	$4.91	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence.
F2	This number reflects a decrease of ownership of 6 shares of common stock from the number of shares previously reported due to an administrative error at the time of the Issuer's 1-for-20 split on July 31, 2020.

Content

The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence.

This number reflects a decrease of ownership of 6 shares of common stock from the number of shares previously reported due to an administrative error at the time of the Issuer's 1-for-20 split on July 31, 2020.